Karyopharm Therapeutics Investor Presentation — August 2020

Document content

Investor Conference Call:

Second Quarter 2020 Financial Results and Business Update

August 4, 20202 ©2020 Karyopharm Therapeutics Inc. On Today’s Call

•Michael G. Kauffman, MD, PhD, Chief Executive Officer

•John Demaree, Chief Commercial Officer

•Mike Mason, MBA, Chief Financial Officer

•Sharon Shacham, PhD, President and Chief Scientific Officer

•Christopher Primiano, JD, MBA ,Chief Business Officer & General Counsel

•Ian Karp, MBA, Senior Vice President, Investor and Public RelationsPrepared

Q&A Session3 ©2020 Karyopharm Therapeutics Inc. This presentation contains forward -looking statements within themeaning ofThePrivate Securities Litigation Reform Actof1995. Such forward -looking statements include those regarding

Karyopharm’s expectations andplans relating toXPOVIO forthetreatment ofpatients withrelapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-celllymphoma ;

commercialization ofXPOVIO oranyofitsdrug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview andpotential approval ofselinexor by,regulatory

authorities, including theCompany’s regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions byregulatory authorities

andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;thetherapeutic potential ofandpotential clinical development plans for

Karyopharm's drug candidates, especially selinexor ;Karyopharm’s collaboration efforts with third-parties, including theNational Cancer Institute ;2020 financial expectations, including